Nitroxyl: A vasodilator of human vessels that is not susceptible to tolerance

Clinical Science

Volumn 129, Issue 2, 2015, Pages 179-187

  Andrews, Karen L ^a   Lumsden, Natalie G ^a   Farry, Julie ^a   Jefferis, Ann Maree ^a   Kemp Harper, Barbara K ^b   Chin Dusting, Jaye P F ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Human radial artery; Human saphenous vein; Nitrate tolerance; Nitroxyl; Vasodilation

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; CYSTEINE; GLYCERYL TRINITRATE; NITRIC OXIDE; NITROXYL; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; CELL RECEPTOR; CYCLIC GMP; ENZYME INHIBITOR; GUANYLATE CYCLASE; NITRIC OXIDE DONOR; NITRITE; NITROGEN OXIDE; OXYHYPONITRITE; POTASSIUM CHANNEL BLOCKING AGENT; SOLUBLE GUANYLYL CYCLASE; VASODILATOR AGENT;

ARTICLE; BLOOD VESSEL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG POTENCY; HUMAN; PRIORITY JOURNAL; RADIAL ARTERY; SAPHENOUS VEIN; VASODILATATION; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; DRUG TOLERANCE; IN VITRO STUDY; METABOLISM; PHYSIOLOGY;

CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; ENZYME INHIBITORS; GUANYLATE CYCLASE; HUMANS; IN VITRO TECHNIQUES; NITRIC OXIDE DONORS; NITRITES; NITROGEN OXIDES; NITROGLYCERIN; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, VOLTAGE-GATED; RADIAL ARTERY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SAPHENOUS VEIN; VASODILATION; VASODILATOR AGENTS;

EID: 84935446807     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20140759     Document Type: Article

References (44)

1. Marsh, N. and Marsh, A. (2000) A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clin. Exp. Pharmacol. Physiol. 27, 313-319.
2. Brunton, L. (1867) On the use of nitrate of amyl in angina pectoris. Lancet ii, 97-98.
3. Munzel, T., Daiber, A. and Gori, T. (2011) Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation 123, 2132-2144.
4. Bullen, M.L., Miller, A.A., Andrews, K.L., Irvine, J.C., Ritchie, R.H., Sobey, C.G. and Kemp-Harper, B.K. (2011) Nitroxyl (HNO) as a vasoprotective signaling molecule. Antioxid. Redox Signal. 14, 1675-1686.
5. Irvine, J.C., Ritchie, R.H., Favaloro, J.L., Andrews, K.L., Widdop, R.E. and Kemp-Harper, B.K. (2008) Nitroxyl (HNO): the Cinderella of the nitric oxide story. Trends Pharmcol. Sci. 29, 601-608.
6. Andrews, K.L., Irvine, J.C., Tare, M., Apostolopoulos, J., Favaloro, J.L., Triggle, C.R. and Kemp-Harper, B.K. (2009) A role for nitroxyl (HNO) as an endothelium-derived relaxing and hyperpolarizing factor in resistance arteries. Br. J. Pharmacol. 157, 540-550.
7. Ellis, A., Li, C.G. and Rand, M.J. (2000) Differential actions of L-cysteine on responses to nitric oxide, nitroxyl anions and EDRF in the rat aorta. Br. J. Pharmacol. 129, 315-322.
8. Favaloro, J.L. and Kemp-Harper, B.K. (2007) The nitroxyl anion (HNO) is a potent dilator of rat coronary vasculature. Cardiovasc. Res. 73, 587-596.
9. Fukuto, J.M., Bartberger, M.D., Dutton, A.S., Paolocci, N., Wink, D.A. and Houk, K.N. (2005) The physiological chemistry and biological activity of nitroxyl (HNO): the neglected, misunderstood, and enigmatic nitrogen oxide. Chem. Res. Toxicol. 18, 790-801.
10. Irvine, J.C., Favaloro, J.L. and Kemp-Harper, B.K. (2003) NO-activates soluble guanylate cyclase and Kv channels to vasodilate resistance arteries. Hypertension 41, 1301-1307.
11. Wanstall, J.C., Jeffery, T.K., Gambino, A., Lovren, F. and Triggle, C.R. (2001) Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide and nitroxyl ion. Br. J. Pharmacol. 134, 463-472.
12. Paolocci, N., Saavedra, W.F., Miranda, K.M., Martignani, C., Isoda, T., Hare, J.M., Espey, M.G., Fukuto, J.M., Feelisch, M., Wink, D.A. and Kass, D.A. (2001) Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling. Proc. Nat. Acad. Sci. U.S.A. 98, 10463-10468.
13. Irvine, J.C., Kemp-Harper, B.K. and Widdop, R.E. (2011) Chronic administration of the HNO donor Angeli's salt does not lead to tolerance, cross-tolerance, or endothelial dysfunction: comparison with GTN and DEA/NO. Antioxid. Redox Signal. 14, 1615-1624.
14. Irvine, J.C., Ravi, R.M., Kemp-Harper, B.K. and Widdop, R.E. (2013) Nitroxyl donors retain their depressor effects in hypertension. Am. J. Physiol. Heart Circ. Physiol. 305, H939-H945.
15. Paolocci, N., Katori, T., Champion, H.C., St. John, M.E., Miranda, K.M., Fukuto, J.M., Wink, D.A. and Kass, D.A. (2003) Positive inotropic and lusitropic effects of HNO/NO-in failing hearts: independence from β-adrenergic signaling. Proc. Nat. Acad. Sci. U.S.A. 100, 5537-5542.
16. Favaloro, J.L. and Kemp-Harper, B.K. (2009) Redox variants of NO (NO· and HNO) elicit vasorelaxation of resistance arteries via distinct mechanisms. Am. J. Physiol. Heart Circ. Physiol. 296, H1274-H1280.
17. Sampson, L., Plane, F. and Garland, C. (2001) Involvement of cyclic GMP and potassium channels in relaxation evoked by the nitric oxide donor, diethylamine NONOate, in the rat small isolated mesenteric artery. Naunyn Schmiedebergs Arch. Pharmacol. 364, 220-225.
18. Irvine, J.C., Favaloro, J.L., Widdop, R.E. and Kemp-Harper, B.K. (2007) Nitroxyl anion donor, Angeli's salt, does not develop tolerance in rat isolated aortae. Hypertension 49, 885-892.
19. Bullen, M.L., Miller, A.A., Dharmarajah, J., Drummond, G.R., Sobey, C.G. and Kemp-Harper, B.K. (2011) Vasorelaxant and antiaggregatory actions of the nitroxyl donor isopropylamine NONOate are maintained in hypercholesterolemia. Am. J. Physiol. Heart Circ. Physiol. 301, H1405-H1414.
20. Donzelli, S., Fischer, G., King, B.S., Niemann, C., DuMond, J.F., Heeren, J., Wieboldt, H., Baldus, S., Gerloff, C., Eschenhagen, T. et al. (2013) Pharmacological characterization of 1-nitrosocyclohexyl acetate, a long-acting nitroxyl donor that shows vasorelaxant and antiaggregatory effects. J. Pharmacol. Exp. Ther. 344, 339-347.
21. Sabbah, H.N., Tocchetti, C.G., Wang, M., Daya, S., Gupta, R.C., Tunin, R.S., Mazhari, R., Takimoto, E., Paolocci, N., Cowart, D. et al. (2013) Nitroxyl (HNO): a novel approach for the acute treatment of heart failure. Circ. Heart Fail. 6, 1250-1258.
22. Aldasoro, M., Mauricio, M.D., Serna, E., Cortina, B., Segarra, G., Medina, P., Vila, J.M., Flor, B. and Lluch, S. (2008) Effects of aspirin, nimesulide, and SC-560 on vasopressin-induced contraction of human gastroepiploic artery and saphenous vein. Crit. Care. Med. 36, 193-197.
23. Hamilton, C.A., McPhaden, A.R., Berg, G., Pathi, V. and Dominiczak, A.F. (2001) Is hydrogen peroxide an EDHF in human radial arteries? Am. J. Physiol. Heart. Circ. Physiol. 280, H2451-H2455.
24. Molenaar, P., Malta, E., Jones, C.R., Buxton, B.F. and Summers, R.J. (1988) Autoradiographic localization and function of beta-adrenoceptors on the human internal mammary artery and saphenous vein. Br. J. Pharmacol. 95, 225-233.
25. Sogo, N., Campanella, C., Webb, D.J. and Megson, I.L. (2000) S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. Br. J. Pharmacol. 131, 1236-1244.
26. Verma, S., Lovren, F., Dumont, A.S., Mather, K.J., Maitland, A., Kieser, T.M., Triggle, C.R. and Anderson, T.J. (2000) Tetrahydrobiopterin improves endothelial function in human saphenous veins. J. Thorac. Cardiovasc. Surg. 120, 668-671.
27. Munzel, T., Hink, U., Yigit, H., Macharzina, R., Harrison, D.G. and Mulsch, A. (1999) Role of superoxide dismutase in in vivo and in vitro nitrate tolerance. Br. J. Pharmacol. 127, 1224-1230.
28. Rapoport, R.M., Waldman, S.A., Ginsburg, R., Molina, C.R. and Murad, F. (1987) Effects of glyceryl trinitrate on endothelium-dependent and-independent relaxation and cyclic GMP levels in rat aorta and human coronary artery. J. Cardiovasc. Pharmacol. 10, 82-89.
29. MacAllister, R.J., Calver, A.L., Riezebos, J., Collier, J. and Vallance, P. (1995) Relative potency and arteriovenous selectivity of nitrovasodilators on human blood vessels: an insight into the targeting of nitric oxide delivery. J. Pharmacol. Exp. Ther. 273, 154-160.
30. Schulz, E., Tsilimingas, N., Rinze, R., Reiter, B., Wendt, M., Oelze, M., Woelken-Weckmuller, S., Walter, U., Reichenspurner, H., Meinertz, T. and Munzel, T. (2002) Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation 105, 1170-1175.
31. Daiber, A., Oelze, M., Coldewey, M., Bachschmid, M., Wenzel, P., Sydow, K., Wendt, M., Kleschyov, A.L., Stalleicken, D., Ullrich, V. et al. (2004) Oxidative stress and mitochondrial aldehyde dehydrogenase activity: a comparison of pentaerythritol tetranitrate with other organic nitrates. Mol. Pharmacol. 66, 1372-1382.
32. Li, C.G. and Rand, M.J. (1993) Effects of hydroxocobalamin and haemoglobin on no-mediated relaxations in the rat anococcygeus muscle. Clin. Exp. Pharmacol. Physiol. 20, 633-640.
33. Qin, X., Zheng, X., Qi, H., Dou, D., Raj, J.U. and Gao, Y. (2007) cGMP-dependent protein kinase in regulation of basal tone and in nitroglycerin-and nitric-oxide-induced relaxation in porcine coronary artery. Pflugers Arch. 454, 913-923.
34. Dierks, E.A. and Burstyn, J.N. (1996) Nitric oxide (NO), the only nitrogen monoxide redox form capable of activating soluble guanylyl cyclase. Biochem. Pharmacol. 51, 1593-1600.
35. Miller, T.W., Cherney, M.M., Lee, A.J., Francoleon, N.E., Farmer, P.J., King, S.B., Hobbs, A.J., Miranda, K., Burstyn, J.N. and Fukuto, J.M. (2009) The effects of nitroxyl (HNO) on soluble guanylate cyclase activity: interactions at ferrous heme and cysteine thiols. J. Biol. Chem. 284, 21788-21796.
36. Zeller, A., Wenzl, M.V., Berretta, M., Stessel, H., Russwurm, M., Koesling, D., Schmidt, K. and Mayer, B. (2009) Mechanisms underlying activation of soluble guanylate cyclase by the HNO donor Angeli's salt. Mol. Pharmacol. 5, 1115-1122.
37. Miranda, K.M., Paolocci, N., Katori, T., Thomas, D., Ford, E., Bartberger, M., Espey, M.G., Kass, D., Feelisch, M., Fukuto, J.M. and Wink, D.A. (2003) A biochemical rationale for the discrete behaviour of nitroxyl and nitric oxide in the cardiovascular system. Proc. Nat. Acad. Sci. U.S.A. 100, 9196-9201.
38. Sand, A., Andersson, E. and Fried, G. (2006) Nitric oxide donors mediate vasodilation in human placental arteries partly through a direct effect on potassium channels. Placenta 27, 181-190.
39. Hamilton, C.A., Berg, G., McArthur, K., Reid, J.L. and Dominiczak, A.F. (1999) Does potassium channel opening contribute to endothelium-dependent relaxation in human internal thoracic artery? Clin. Sci. 96, 631-638.
40. Zhang, Y., Tazzeo, T., Chu, V. and Janssen, L.J. (2006) Membrane potassium currents in human radial artery and their regulation by nitric oxide donor. Cardiovasc. Res. 71, 383-392.
41. DeMots, H. and Glasser, S.P. (1989) Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J. Am. Coll. Cardiol. 13, 786-795.
42. Ferratini, M., Pirelli, S., Merlini, P., Silva, P. and Pollavini, G. (1989) Intermittent transdermal nitroglycerin monotherapy in stable exercise-induced angina: a comparison with a continuous schedule. Eur. Heart J. 10, 998-1002.
43. Hink, U., Daiber, A., Kayhan, N., Trischler, J., Kraatz, C., Oelze, M., Mollnau, H., Wenzel, P., Vahl, C.F., Ho, K.K. et al. (2007) Oxidative inhibition of the mitochondrial aldehyde dehydrogenase promotes nitroglycerin tolerance in human blood vessels. J. Am. Coll. Cardiol. 50, 2226-2232.
44. Mollnau, H., Wenzel, P., Oelze, M., Treiber, N., Pautz, A., Schulz, E., Schuhmacher, S., Reifenberg, K., Stalleicken, D., Scharffetter-Kochanek, K. et al. (2006) Mitochondrial oxidative stress and nitrate tolerance-comparison of nitroglycerin and pentaerithrityl tetranitrate in Mn-SOD+/-mice. BMC Cardiovasc. Disord. 6, 44.